Journal
ACS CHEMICAL NEUROSCIENCE
Volume 11, Issue 15, Pages 2173-2191Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acschemneuro.0c00358
Keywords
Retinitis pigmentosa; Wnt/beta-catenin/GSK beta; apoptosis; growth factors; GPCRs; HDAC
Funding
- MIUR Grant Dipartimento di Eccellenza 2018-2022 [l. 232/2016]
- Tuscany strategic project POR-FSE 2014 to 2020, Medicina di Precisione e Malattie Rare (MePreMaRe), (ACE-ESCC)
Ask authors/readers for more resources
Inherited retinal diseases (IRDs) are a group of etinopatliies generally caused by genetic mutations. F.etinitis Pigmentosa (RP) rePresenotsone of the most studied IRDs. RP leads to intense vision loss or blindness resulting from the degeneration of photoreceptor cells. To date, RP is mainly treated with palliative suPPlementation of BitaminA a pharmacologicallyretinoids, gene therapies, or surgical interventions. Therefore based therapy is an urgent need requiring a medicinal chemistry approach, to validate molecular targets able to deal with retinal Rdegeneration. This Review aims at outlining the recent research drugefforts in identifying new targets for RP, especially focusing on the neuroprotective role of the Wnt/beta-catenin/GSK3 beta pathwayand apoptosis modulators (in particular FikRF-1) but also on growth factors such as VEGF and BDNF. FuiThermure, the ruie of spatiotempiirally expressed G protein-coupled receptors. (GpR124) in the retina and the emerging function of histone deacetylase inhibitors in promoting retinal neuroprotection will be discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available